Clinical trial · Interventional
Multiparametric PET-MRI Integration for a New Approach to Tumor Heterogeneity in Non-Small Cell Lung Cancer (NSCLC): Pilot Study
NCT03606070CI-TRIAL-00122857IMAHTEPterminatedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Lack of inclusion
Summary
Brief summary (as posted)
To estimate the intra and inter-operator reproducibility of multiparametric regional PET-MRI mapping in locally advanced and trace mestastatic non-small cell lung cancer (NSCLC).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| NSCLC | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PET-MRI | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Patients with NSCLC
- description
- Characterization of tumor heterogeneity by multiparametric regional mapping PET-MRI. Patients will realize: * a PET-MRI examination performed before the chemoradiotherapy treatment (so-called baseline PET-MRI) * a PET-MRI examination performed midway through treatment (PET-MRI1 under treatment), after receiving 33 ± 4 Gy (approximately 2.5 months after the first PET-MRI).
- interventionNames
- Diagnostic Test: PET-MRI
Primary outcomes (1)
- measure
- Measurement of intra and inter-operator reproducibility of multiparametric regional PET-MRI mapping performed before and under treatment.
- timeFrame
- Up to 24 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Locally advanced NSCLC (stages IIB, IIIA or IIIB of the TNM classification 7th edition) or trace metastatic stage IV (\</=5 mestastasis, \</= 3 organ reached) 2. Exclusive therapeutic management by concomitant radio-chemotherapy administered in accordance with international recommendations (dual therapy with platinum salts) 3. Signed consent 4. Patients affiliated with the social security scheme or beneficiary of a similar scheme. Exclusion Criteria: 1. Minor 2. Pregnant / lactating woman 3. Person deprived of liberty by judicial or administrative decision, adults who are the subject of a legal protection measure or unable to express their consent 4. Previous cancer in the 2 years prior to registration 5. Previousradiotherapy / thoracic surgery 6. Patients under experimental treatment or for whom the administration of an experimental treatment is planned 7. Claustrophobic patients 8. Severe Renal Insufficiency (Clearance MDRD Cockroft \<30ml / min) 9. Uncontrolled diabetes, hyperglycemia\> 1.8g / L 10. Patient with metallic implants not compatible with MRI or any immovable implanted electronic medical device (eg pacemaker, neurostimulator, cochlear implants, etc.)
References
Publications (1)
- RESULTBesson FL, Fernandez B, Faure S, Mercier O, Seferian A, Mignard X, Mussot S, le Pechoux C, Caramella C, Botticella A, Levy A, Parent F, Bulifon S, Montani D, Mitilian D, Fadel E, Planchard D, Besse B, Ghigna-Bellinzoni MR, Comtat C, Lebon V, Durand E. 18F-FDG PET and DCE kinetic modeling and their correlations in primary NSCLC: first voxel-wise correlative analysis of human simultaneous [18F]FDG PET-MRI data. EJNMMI Res. 2020 Jul 30;10(1):88. doi: 10.1186/s13550-020-00671-9. PMID 32734484